Related Experiment Videos
Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats
K Sugimoto1, S Tsuruoka, K Matsushita
1Department of Clinical Pharmacology, Jichi Medical School, Tochigi, Japan.
Abstract:
We have investigated the influence of a novel angiotensin II type 1 receptor antagonist, candesartan cilexetil, on the oxidative state of renal tissue and renal function in 5/6 nephrectomized rats, and compared its effects with those of an angiotensin-converting enzyme inhibitor, enalapril. Candesartan cilexetil (1 and 5 mg/kg per day), enalapril (5 mg/kg per day) and vehicle were orally administered once daily for 16 weeks after 5/6 nephrectomy. There was a marked degree of proteinuria evident prior to treatment, an average of 5.69 mg/mg creatinine in the nephrectomized rats, vs 1 to 2 mg/mg creatinine in the control group matched for species and body weight. Inhibition of development of proteinuria by candesartan cilexetil was dose dependent. Enalapril also significantly blunted the rise in urinary protein. Malondi-aldehyde content in the homogenate from the renal cortex increased significantly in the nephrectomized rats compared to control animals. This elevation of malondi-aldehyde content was unaffected by administration of either candesartan cilexetil or enalapril. Antioxidative enzyme (glutathione peroxidase, superoxide dismutase, and catalase) activities in the renal tissue were not affected by any active treatment. Elevation of lipid peroxide in remnant renal tissue suggests that oxidative stress may contribute to the progression of renal injury in the nephrectomized rats. Neither candesartan cilexetil nor enalapril affected antioxidant defenses in renal tissue in nephrectomized rats, indicating that mechanisms other than alteration in oxidative stress are involved in the renoprotective effects of candesartan cilexetil and enalapril.
Insights
Candesartan cilexetil and enalapril reduced proteinuria in rats with chronic kidney disease. However, neither drug altered oxidative stress markers in renal tissue, suggesting renoprotective effects stem from mechanisms beyond antioxidant defenses.
Area of Science:
- Nephrology
- Pharmacology
- Oxidative Stress Research
Background:
- Chronic kidney disease (CKD) progression is linked to oxidative stress.
- Angiotensin II type 1 receptor antagonists and ACE inhibitors are used to treat CKD.
Purpose of the Study:
- To investigate the effects of candesartan cilexetil on renal oxidative status and function in 5/6 nephrectomized rats.
- To compare these effects with enalapril.
Main Methods:
- 5/6 nephrectomized rats were treated with candesartan cilexetil (1, 5 mg/kg), enalapril (5 mg/kg), or vehicle for 16 weeks.
- Proteinuria, malondialdehyde (MDA) content, and antioxidant enzyme activities (glutathione peroxidase, superoxide dismutase, catalase) were measured.
Main Results:
- Both candesartan cilexetil (dose-dependent) and enalapril significantly reduced proteinuria.
- MDA levels, indicating lipid peroxidation, were elevated in nephrectomized rats but unaffected by treatments.
- Antioxidant enzyme activities remained unchanged in all treatment groups.
Conclusions:
- Candesartan cilexetil and enalapril demonstrate renoprotective effects by reducing proteinuria in this CKD model.
- These benefits appear independent of alterations in renal oxidative stress or antioxidant enzyme activity.
- Other mechanisms likely mediate the renoprotective actions of these drugs.